Concepedia

Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia

Joshua F. Zeidner, Daniel J. Lee, Mark G. Frattini, Gil D. Fine, Judy Costas, Kathryn S. Kolibaba, Stephen P. Anthony, David J. Bearss, B. Douglas Smith

Clinical Cancer Research · 2020 · 25 citations · 37 references

DOIFull text

Open access

Abstract

Alvocidib can be safely administered prior to 7+3 induction with encouraging clinical activity. These findings warrant further investigation of alvocidib combinations in newly diagnosed AML. This study was registered at clinicaltrials.gov identifier NCT03298984.

References

37

Cancer statistics, 2020

Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2020 · 21K citations · Full text

Genomic Classification and Prognosis in Acute Myeloid Leukemia

Elli Papaemmanuil, Moritz Gerstung, Lars Bullinger et al. · New England Journal of Medicine · 2016 · 4.2K citations · Full text

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation

Richard M. Stone, Sumithra J. Mandrekar, Ben L. Sanford et al. · New England Journal of Medicine · 2017 · 2.1K citations · Full text

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study

Marilyn L. Slovak, Kenneth J. Kopecky, Peter A. Cassileth et al. · Blood · 2000 · 1.6K citations

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

Sylvie Castaigné, Cécile Pautas, Christine Terré et al. · The Lancet · 2012 · 975 citations

, , +8